Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pediatr Nephrol. 2011 Jul;26(7):1001-15. doi: 10.1007/s00467-010-1692-x. Epub 2010 Nov 26.

Pathogenesis and therapy of focal segmental glomerulosclerosis: an update.

Author information

  • 1Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA. rasheed.gbadegesin@duke.edu

Abstract

Focal and segmental glomerulosclerosis (FSGS) is an important cause of steroid-resistant nephrotic syndrome in adults and children. It is responsible for 5-20% of all cases of end-stage kidney disease (ESKD) in the United States. The pathogenesis of FSGS has not been fully elucidated; however, data from molecular studies of familial cases in the last two decades suggest that FSGS is a defect of the podocyte. The therapeutic agents available for treatment of FSGS are not very effective and only a small percentage of affected individuals will achieve complete remission. Recent data from molecular biology and molecular genetics has provided insight into the mechanisms of action of old agents and also identification of other novel therapeutic targets. This review focuses on recent advances in the molecular pathogenesis of FSGS and currently available therapeutic agents as well as potential novel therapies.

PMID:
21110043
[PubMed - indexed for MEDLINE]
PMCID:
PMC3624015
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk